Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Phase 3 Trial of Ipilimumab After Bone-Directed Radiotherapy in Castration-Resistant Prostate Cancer
2008-003314-97Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Ipilimumab arm with Placebo arm (2 arms). Primary endpoint: Overall survival. Started Apr 2009; status: terminated.
02
Drugs
ipilimumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-003314-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003314-97.